Blog

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

JTVCdGVhbV9qdW1wX2xpc3QlNUQ= May 8, 2026 At Certainty 2026, the Phoenix User Group Meeting brought together scientists,…

CertaraMay 8, 2026

On-Demand Webinar

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

Explore how Phoenix NLME and RsNLME support early phase clinical pharmacology workflows where speed, clarity,…

CertaraMay 6, 2026

Blog

GxP compliance in the cloud: What IT teams need to rethink

Learn how GxP validation works in modern SaaS and cloud environments, with best practices for…

CertaraMay 4, 2026

Webinar

Allometric Approach in pharmacokinetics when and how to use it

Danielle PillsburyApril 28, 2026

Webinar

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

CertaraApril 10, 2026

Blog

PK parameters explained: From Cmax to clearance (and why it matters for development decisions)

Learn how key PK parameters such as Cmax, AUC, clearance, half life, and volume of…

CertaraApril 9, 2026

On-Demand Webinar

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Watch this on-demand webinar to learn how the final ICH M15 guidance is shaping Model-Informed…

CertaraApril 2, 2026

Case Study

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

PK/PD Modeling for CNS drug development using Phoenix NLME and machine learning for better CNS…

CertaraMarch 26, 2026

Publication

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

This study evaluated the pharmacokinetics (PK) and pharmacokinetic–pharmacodynamic (PK–PD) relationship of clazakizumab, an anti–interleukin-6 (IL-6)…

Danielle PillsburyMarch 24, 2026

Guide

From Numbers to Narrative: Mastering the Art of PK Presentation

Master PK data reporting with a structured guide to presenting pharmacokinetic results clearly and turning…

CertaraMarch 20, 2026

Certara Products – Phoenix

What we learned at Phoenix UGM at Certainty 2026 about the future of PK/PD

Pharmacometrics Under Pressure: The Quantitative Clinical Pharmacology Sprint

GxP compliance in the cloud: What IT teams need to rethink

Allometric Approach in pharmacokinetics when and how to use it

When pharmacokinetics meets pharmacogenomics: Genetic Insights into Fluoxetine PK for Personalized Antidepressant Therapy

PK parameters explained: From Cmax to clearance (and why it matters for development decisions)

Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations

Integrated PK/PD Modeling and Machine Learning to Support CNS Compound Selection

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Analysis for Clazakizumab in Patients With End-Stage Kidney Disease Undergoing Dialysis

From Numbers to Narrative: Mastering the Art of PK Presentation

Newsletter sign up

Quick links

Solutions

Contact